- Tips for Spending Holiday Time With Family Members Who Live with Dementia
- Tainted Cucumbers Now Linked to 100 Salmonella Cases in 23 States
- Check Your Pantry, Lay’s Classic Potato Chips Recalled Due to Milk Allergy Risk
- Norovirus Sickens Hundreds on Three Cruise Ships: CDC
- Not Just Blabber: What Baby’s First Vocalizations and Coos Can Tell Us
- What’s the Link Between Memory Problems and Sexism?
- Supreme Court to Decide on South Carolina’s Bid to Cut Funding for Planned Parenthood
- Antibiotics Do Not Increase Risks for Cognitive Decline, Dementia in Older Adults, New Data Says
- A New Way to Treat Sjögren’s Disease? Researchers Are Hopeful
- Some Abortion Pill Users Surprised By Pain, Study Says
New Device Treats Superficial Varicose Veins
The VenaSeal closure system has been approved by the U.S. Food and Drug Administration to treat superficial varicose veins in the leg that appear close to the skin and cause an unsightly and sometimes painful condition.
The product, administered by a trained professional, is designed to seal the affected veins, preventing the pooling of blood in these vessels. It was clinically evaluated in a study of more than 200 participants, comparing it to another treatment called radio-frequency ablation.
“The trials showed the device to be safe and effective for vein closure for the treatment of symptomatic superficial varicose veins of the legs,” the FDA said Friday in a news release.
The VenaSeal system should not be used in people with a known sensitivity to the system’s adhesive, or in those with inflamed veins due to blood clots or infection. The most common side effects included vein inflammation and burning and tingling in the treatment area, the agency said.
The VenaSeal system is manufactured by Covidien LLC, in Morrisville, N.C.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.